Age-associated difference in circulating ACE2, the gateway for SARS-COV-2, in humans: results from the InCHIANTI study
| العنوان: | Age-associated difference in circulating ACE2, the gateway for SARS-COV-2, in humans: results from the InCHIANTI study |
|---|---|
| المؤلفون: | Luigi Ferrucci, Stefania Bandinelli, Ann Zenobia Moore, Edward G. Lakatta, Toshiko Tanaka, Majd AlGhatrif |
| المصدر: | GeroScience |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Aging, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ACE2, Angiotensin-Converting Enzyme Inhibitors, Inflammation, Disease, Peptidyl-Dipeptidase A, Angiotensin Receptor Antagonists, chemistry.chemical_compound, Statistical significance, Internal medicine, Humans, Medicine, Aged, Aldosterone, SARS-CoV-2, business.industry, COVID-19, Cardiovascular disease, Molecular medicine, Ageing, Italy, chemistry, Cohort, Original Article, Angiotensin-Converting Enzyme 2, Geriatrics and Gerontology, medicine.symptom, business, hormones, hormone substitutes, and hormone antagonists |
| الوصف: | Levels of angiotensin-converting enzyme 2 (ACE2), the gateway for COVID-19 virus into the cells, have been implicated in worse COVID-19 outcomes associated with aging and cardiovascular disease (CVD). Data on age-associated differences in circulating ACE2 levels in humans and the role of CVD and medications is limited. We analyzed data from 967 participants of the InCHIANTI study, a community-dwelling cohort in the Chianti region, Italy. Relative abundance of ACE2 in plasma was assessed using a proteomics platform. CVD diagnoses, use of renin-angiotensin-aldosterone system (RAAS) antagonists: ACEi, ARBs, and aldosterone antagonists, were ascertained. Multiple linear analyses were performed to examine the independent association of ACE2 with age, CVD, and RAAS antagonist use. Age was independently associated with lower log (ACE2) in persons aged ≥ 55 years (STD β = − 0.12, p = 0.0002). ACEi treatment was also independently associated with significantly lower ACE2 levels, and ACE2 was inversely associated with weight, and positively associated with peripheral artery disease (PAD) status. There was a trend toward higher circulating ACE2 levels in hypertensive individuals, but it did not reach statistical significance. In a stratified analysis, the association between log (ACE2) and log (IL-6) was more evidenced in participants with PAD. Circulating ACE2 levels demonstrate curvilinear association with age, with older individuals beyond the sixth decade age having lower levels. ACEi was associated with greater circulating ACE2 levels. Interestingly, ACE2 was elevated in PAD and positively associated with inflammatory markers, suggesting compensatory upregulation in the setting of chronic inflammation. Further studies are needed to comprehensively characterize RAAS components with aging and disease, and assess its prognostic role in predicting COVID-19 outcomes. |
| تدمد: | 2509-2723 2509-2715 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::119cc7f978df62fe4b55d00fd490c7b4Test https://doi.org/10.1007/s11357-020-00314-wTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....119cc7f978df62fe4b55d00fd490c7b4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 25092723 25092715 |
|---|